{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:15:58Z","timestamp":1789676158923,"version":"4.0.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","award":["R56NR020466"],"award-info":[{"award-number":["R56NR020466"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11920-025-01601-z","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T03:33:48Z","timestamp":1742268828000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sex Differences in Obesity and Its Treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"Aleena","family":"Ghanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana M.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"10431","key":"1601_CR1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027\u201350.","journal-title":"Lancet"},{"issue":"3","key":"1601_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2213-8587(19)30026-9","volume":"7","author":"LM Jaacks","year":"2019","unstructured":"Jaacks LM, Vandevijvere S, Pan A, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1601_CR3","doi-asserted-by":"crossref","unstructured":"Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex\/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep. 2021:1\u20139. ** This literature review evaluated the influence of sex and gender on obesity prevalence and its comorbidities.","DOI":"10.1007\/s13679-021-00453-x"},{"key":"1601_CR4","unstructured":"Lobstein T, Brinsden H, Neveux M. World obesity atlas 2022. 2022."},{"key":"1601_CR5","unstructured":"National Academies of Sciences E. Medicine. Measuring sex, gender identity, and sexual orientation. 2022."},{"issue":"3","key":"1601_CR6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1017\/S1368980021000768","volume":"25","author":"R Pradeilles","year":"2022","unstructured":"Pradeilles R, Holdsworth M, Olaitan O, et al. Body size preferences for women and adolescent girls living in Africa: a mixed-methods systematic review. Public Health Nutr. 2022;25(3):738\u201359.","journal-title":"Public Health Nutr"},{"key":"1601_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12937-018-0330-5","volume":"17","author":"DA Naigaga","year":"2018","unstructured":"Naigaga DA, Jahanlu D, Claudius HM, Gjerlaug AK, Barikmo I, Henjum S. Body size perceptions and preferences favor overweight in adult Saharawi refugees. Nutr J. 2018;17:1\u20138.","journal-title":"Nutr J"},{"key":"1601_CR8","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u2013216. *This study examined the efficacy and safety of tirzepatide in people with obesity in a phase 3 double-blind, randomized, controlled trial.","DOI":"10.1056\/NEJMoa2206038"},{"issue":"11","key":"1601_CR9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"key":"1601_CR10","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"1601_CR11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00125-019-05040-3","volume":"63","author":"B Tramunt","year":"2020","unstructured":"Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63:453\u201361.","journal-title":"Diabetologia"},{"issue":"1","key":"1601_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41574-020-00431-8","volume":"17","author":"GH Goossens","year":"2021","unstructured":"Goossens GH, Jocken JW, Blaak EE. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat Rev Endocrinol. 2021;17(1):47\u201366.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1601_CR13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66(6):986\u20131002.","journal-title":"Diabetologia"},{"issue":"3","key":"1601_CR14","first-page":"96","volume":"26","author":"P Estoppey","year":"2023","unstructured":"Estoppey P, Clair C, Auderset D, Puder JJ. Sex differences in type 2 diabetes. Cardiovasc Med. 2023;26(3):96\u20139.","journal-title":"Cardiovasc Med"},{"issue":"1","key":"1601_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2337\/diacare.26.1.61","volume":"26","author":"DS Group","year":"2003","unstructured":"Group DS. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26(1):61\u20139.","journal-title":"Diabetes Care"},{"key":"1601_CR16","doi-asserted-by":"crossref","first-page":"1368966","DOI":"10.3389\/fnut.2024.1368966","volume":"11","author":"M Alser","year":"2024","unstructured":"Alser M, Naja K, Elrayess MA. Mechanisms of body fat distribution and gluteal-femoral fat protection against metabolic disorders. Front Nutr. 2024;11:1368966. This article examined how body fat distribution, rather than general obesity, is considered a more accurate factor associated with metabolic diseases.","journal-title":"Front Nutr"},{"issue":"1","key":"1601_CR17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41591-020-1126-7","volume":"27","author":"T Becher","year":"2021","unstructured":"Becher T, Palanisamy S, Kramer DJ, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27(1):58\u201365.","journal-title":"Nat Med"},{"issue":"3","key":"1601_CR18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2015-1137","volume":"37","author":"A Kautzky-Willer","year":"2016","unstructured":"Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endoc Rev. 2016;37(3):278\u2013316.","journal-title":"Endoc Rev"},{"issue":"9","key":"1601_CR19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-019-0563-7","volume":"25","author":"T Karlsson","year":"2019","unstructured":"Karlsson T, Rask-Andersen M, Pan G, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med. 2019;25(9):1390\u20135.","journal-title":"Nat Med"},{"issue":"4","key":"1601_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2337\/dc21-1430","volume":"45","author":"MV Diaz-Santana","year":"2022","unstructured":"Diaz-Santana MV, O\u2019Brien KM, Park Y-MM, Sandler DP, Weinberg CR. Persistence of risk for type 2 diabetes after gestational diabetes mellitus. Diabetes Care. 2022;45(4):864\u201370.","journal-title":"Diabetes Care"},{"issue":"10","key":"1601_CR21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41574-022-00708-0","volume":"18","author":"I Lambrinoudaki","year":"2022","unstructured":"Lambrinoudaki I, Paschou SA, Armeni E, Goulis DG. The interplay between diabetes mellitus and menopause: clinical implications. Nat Rev Endocrinol. 2022;18(10):608\u201322.","journal-title":"Nat Rev Endocrinol"},{"key":"1601_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.smrv.2016.07.002","volume":"34","author":"CV Senaratna","year":"2017","unstructured":"Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017;34:70\u201381.","journal-title":"Sleep Med Rev"},{"key":"1601_CR23","doi-asserted-by":"crossref","unstructured":"Bonsignore MR, Saaresranta T, Riha RL. Sex differences in obstructive sleep Apnoea. Eur Respir Rev. 2019;28(154).","DOI":"10.1183\/16000617.0030-2019"},{"issue":"3","key":"1601_CR24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/ajrccm.163.3.9911064","volume":"163","author":"EO Bixler","year":"2001","unstructured":"Bixler EO, Vgontzas AN, Lin H-m, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001;163(3):608\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1601_CR25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MCP.0000000000000728","volume":"26","author":"SE Schiza","year":"2020","unstructured":"Schiza SE, Bouloukaki I. Does gender matter: sex-specific aspects of symptoms, outcome, and therapy of obstructive sleep apnea. Curr Opin Pulm Med. 2020;26(6):642\u20139.","journal-title":"Curr Opin Pulm Med"},{"issue":"23","key":"1601_CR26","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.284.23.3015","volume":"284","author":"PE Peppard","year":"2000","unstructured":"Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015\u201321.","journal-title":"JAMA"},{"issue":"1","key":"1601_CR27","first-page":"487215","volume":"2014","author":"K-T Huang","year":"2014","unstructured":"Huang K-T, Chin C-H, Tseng C-C, et al. The influence of obesity on different genders in patients with obstructive sleep apnea. Sci World J. 2014;2014(1):487215.","journal-title":"Sci World J"},{"key":"1601_CR28","doi-asserted-by":"crossref","unstructured":"Segal NA, Nilges JM, Oo WM. Sex differences in osteoarthritis prevalence, pain perception, physical function and therapeutics. Osteoarthritis Cartilage. 2024;32(9):1045\u20131053.","DOI":"10.1016\/j.joca.2024.04.002"},{"issue":"14","key":"1601_CR29","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3390\/jcm10143178","volume":"10","author":"M Tschon","year":"2021","unstructured":"Tschon M, Contartese D, Pagani S, Borsari V, Fini M. Gender and sex are key determinants in osteoarthritis not only confounding variables. A systematic review of clinical data. J Clin Med. 2021;10(14):3178.","journal-title":"J Clin Med"},{"issue":"1","key":"1601_CR30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12891-024-07191-w","volume":"25","author":"J Di","year":"2024","unstructured":"Di J, Bai J, Zhang J, et al. Regional disparities, age-related changes and sex-related differences in knee osteoarthritis. BMC Musculoskelet Disord. 2024;25(1):66.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"1601_CR31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.joca.2008.01.002","volume":"16","author":"Y Sniekers","year":"2008","unstructured":"Sniekers Y, Weinans H, Bierma-Zeinstra S, Van Leeuwen J, Van Osch G. Animal models for osteoarthritis: the effect of ovariectomy and Estrogen treatment\u2013a systematic approach. Osteoarthritis Cartilage. 2008;16(5):533\u201341.","journal-title":"Osteoarthritis Cartilage"},{"issue":"7","key":"1601_CR32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.42089","volume":"74","author":"H Long","year":"2022","unstructured":"Long H, Liu Q, Yin H, et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019. Arthritis Rheumatol. 2022;74(7):1172\u201383.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1601_CR33","first-page":"S59","volume":"4","author":"HK Vincent","year":"2012","unstructured":"Vincent HK, Heywood K, Connelly J, Hurley RW. Obesity and weight loss in the treatment and prevention of osteoarthritis. PM R. 2012;4(5):S59\u201367.","journal-title":"PM R"},{"issue":"3","key":"1601_CR34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.joca.2022.10.023","volume":"31","author":"P Solanki","year":"2023","unstructured":"Solanki P, Hussain SM, Abidi J, et al. Association between weight gain and knee osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2023;31(3):300\u201316.","journal-title":"Osteoarthritis Cartilage"},{"issue":"6","key":"1601_CR35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/rheumatology\/keac688","volume":"62","author":"IA Szilagyi","year":"2023","unstructured":"Szilagyi IA, Waarsing JH, van Meurs JB, Bierma-Zeinstra SM, Schiphof D. A systematic review of the sex differences in risk factors for knee osteoarthritis. Rheumatology. 2023;62(6):2037\u201347.","journal-title":"Rheumatology"},{"issue":"2","key":"1601_CR36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/rheumatology\/keab378","volume":"61","author":"IA Szilagyi","year":"2022","unstructured":"Szilagyi IA, Waarsing JH, Schiphof D, Van Meurs JB, Bierma-Zeinstra SM. Towards sex-specific osteoarthritis risk models: evaluation of risk factors for knee osteoarthritis in males and females. Rheumatology. 2022;61(2):648\u201357.","journal-title":"Rheumatology"},{"issue":"3","key":"1601_CR37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cardfail.2021.10.006","volume":"28","author":"A Lala","year":"2022","unstructured":"Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477\u201398.","journal-title":"J Card Fail"},{"issue":"8","key":"1601_CR38","first-page":"701","volume":"6","author":"N Savji","year":"2018","unstructured":"Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC: Heart Fail. 2018;6(8):701\u20139.","journal-title":"JACC: Heart Fail"},{"issue":"6","key":"1601_CR39","doi-asserted-by":"crossref","first-page":"e004396","DOI":"10.1161\/CIRCIMAGING.115.004396","volume":"9","author":"S Selvaraj","year":"2016","unstructured":"Selvaraj S, Martinez EE, Aguilar FG, et al. Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study. Circ Cardiovasc Imaging. 2016;9(6):e004396.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1601_CR40","unstructured":"Chao AM, Moore M, Wadden TA. The past, present, and future of behavioral obesity treatment. Int J Obes. 2024:1\u201310. *This article examined changes over time in behavioral weight-management interventions combining diet, physical activity, and behavior therapy."},{"issue":"1","key":"1601_CR41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.orcp.2015.04.005","volume":"10","author":"C Robertson","year":"2016","unstructured":"Robertson C, Avenell A, Boachie C, et al. Should weight loss and maintenance programmes be designed differently for men? A systematic review of long-term randomised controlled trials presenting data for men and women: the ROMEO project. Obes Res Clin Pract. 2016;10(1):70\u201384.","journal-title":"Obes Res Clin Pract"},{"issue":"11","key":"1601_CR42","doi-asserted-by":"crossref","first-page":"e039295","DOI":"10.1136\/bmjopen-2020-039295","volume":"10","author":"ML Greaney","year":"2020","unstructured":"Greaney ML, Cohen SA, Xu F, Ward-Ritacco CL, Riebe D. Healthcare provider counselling for weight management behaviours among adults with overweight or obesity: a cross-sectional analysis of National health and nutrition examination survey, 2011\u20132018. BMJ Open. 2020;10(11):e039295.","journal-title":"BMJ Open"},{"key":"1601_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-8252-5","volume":"20","author":"M Elliott","year":"2020","unstructured":"Elliott M, Gillison F, Barnett J. Exploring the influences on Men\u2019s engagement with weight loss services: a qualitative study. BMC Public Health. 2020;20:1\u201311.","journal-title":"BMC Public Health"},{"issue":"1","key":"1601_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/obr.12343","volume":"17","author":"J Spahlholz","year":"2016","unstructured":"Spahlholz J, Baer N, K\u00f6nig HH, Riedel-Heller SG, Luck\u2010Sikorski C. Obesity and discrimination\u2013a systematic review and meta\u2010analysis of observational studies. Obes Rev. 2016;17(1):43\u201355.","journal-title":"Obes Rev"},{"key":"1601_CR45","doi-asserted-by":"crossref","first-page":"100755","DOI":"10.1016\/j.ssmph.2021.100755","volume":"13","author":"RL Pearl","year":"2021","unstructured":"Pearl RL, Puhl RM, Lessard LM, Himmelstein MS, Foster GD. Prevalence and correlates of weight bias internalization in weight management: a multinational study. SSM Popul Health. 2021;13:100755.","journal-title":"SSM Popul Health"},{"key":"1601_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12937-019-0518-3","volume":"19","author":"T Sharkey","year":"2020","unstructured":"Sharkey T, Whatnall MC, Hutchesson MJ, et al. Effectiveness of gender-targeted versus gender-neutral interventions aimed at improving dietary intake, physical activity and\/or overweight\/obesity in young adults (aged 17\u201335 years): a systematic review and meta-analysis. Nutr J. 2020;19:1\u201320.","journal-title":"Nutr J"},{"key":"1601_CR47","doi-asserted-by":"crossref","unstructured":"Mast A, Pe\u00f1a A, Bolch CA, Shaibi G, Vander Wyst KB. Sex differences in response to lifestyle intervention among children and adolescents: Systematic review and meta-analysis. Obesity. 2023;31(3):665\u2013692. **This systematic review and meta-analysis assessed sex differences in response to lifestyle intervention among children and adolescents.","DOI":"10.1002\/oby.23663"},{"issue":"3","key":"1601_CR48","doi-asserted-by":"crossref","first-page":"e13148","DOI":"10.1111\/obr.13148","volume":"22","author":"S Chopra","year":"2021","unstructured":"Chopra S, Malhotra A, Ranjan P, et al. Predictors of successful weight loss outcomes amongst individuals with obesity undergoing lifestyle interventions: A systematic review. Obes Rev. 2021;22(3):e13148.","journal-title":"Obes Rev"},{"issue":"2","key":"1601_CR49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/obr.12241","volume":"16","author":"R Williams","year":"2015","unstructured":"Williams R, Wood L, Collins C, Callister R. Effectiveness of weight loss interventions\u2013is there a difference between men and women: a systematic review. Obes Rev. 2015;16(2):171\u201386.","journal-title":"Obes Rev"},{"issue":"6","key":"1601_CR50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.orcp.2022.09.006","volume":"16","author":"A Susanto","year":"2022","unstructured":"Susanto A, Burk J, Hocking S, Markovic T, Gill T. Differences in weight loss outcomes for males and females on a low-carbohydrate diet: A systematic review. Obes Res Clin Pract. 2022;16(6):447\u201356.","journal-title":"Obes Res Clin Pract"},{"issue":"12","key":"1601_CR51","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1111\/dom.13466","volume":"20","author":"P Christensen","year":"2018","unstructured":"Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi\u2010centre intervention study after a low\u2010energy diet in 2500 overweight, individuals with pre\u2010diabetes (PREVIEW). Diabet Obes Metab. 2018;20(12):2840\u201351.","journal-title":"Diabet Obes Metab"},{"key":"1601_CR52","doi-asserted-by":"crossref","unstructured":"Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ. Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review. Lancet Diabetes Endocrinol. 2024;12(6):414\u2013421.","DOI":"10.1016\/S2213-8587(24)00098-6"},{"issue":"14","key":"1601_CR53","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"1601_CR54","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10","key":"1601_CR55","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"6","key":"1601_CR56","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4\u00a0mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050\u201361.","journal-title":"Obesity"},{"issue":"1","key":"1601_CR57","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","volume":"31","author":"CW le Roux","year":"2023","unstructured":"le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity. 2023;31(1):96\u2013110.","journal-title":"Obesity"},{"issue":"11","key":"1601_CR58","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"1601_CR59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"6","key":"1601_CR60","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.joca.2024.03.003","volume":"32","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al. Semaglutide 2.4\u00a0mg efficacy and safety in people with obesity and knee osteoarthritis: results: from the STEP 9 randomised clinical trial. Osteoarthritis Cartilage. 2024;32(6):745\u20136.","journal-title":"Osteoarthritis Cartilage"},{"issue":"10402","key":"1601_CR61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"10278","key":"1601_CR62","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b7 4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"key":"1601_CR63","doi-asserted-by":"crossref","unstructured":"Malhotra A, Grunstein RR, Fietze I et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u20131205.","DOI":"10.1056\/NEJMoa2404881"},{"issue":"10","key":"1601_CR64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990\u20131004.","journal-title":"JAMA"},{"issue":"12","key":"1601_CR65","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","volume":"379","author":"EA Bohula","year":"2018","unstructured":"Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of Lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107\u201317.","journal-title":"N Engl J Med"},{"issue":"24","key":"1601_CR66","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"1601_CR67","unstructured":"Montero A, Sparks G, Presiado M, Hamel L. KFF Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs. [Accessed July 30, 2024]. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/"},{"issue":"11","key":"1601_CR68","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.eprac.2021.07.004","volume":"27","author":"J MacEwan","year":"2021","unstructured":"MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity medication use among overweight and obese adults in the united States: 2015\u20132018. Endocr Pract. 2021;27(11):1139\u201348.","journal-title":"Endocr Pract"},{"key":"1601_CR69","doi-asserted-by":"crossref","unstructured":"Ladebo L, Ernst MT, Mailhac A, Dirksen C, Bojsen-M\u00f8ller KN, Potteg\u00e5rd A. Real-World use of semaglutide for weight management: patient characteristics and dose Titration\u2014A Danish cohort study. Diabetes Care. 2024;47(10):1834\u20131837.","DOI":"10.2337\/dc24-1082"},{"key":"1601_CR70","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","volume":"31","author":"A Elangovan","year":"2021","unstructured":"Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity\u2014trends using a population level National database. Obes Surg. 2021;31:1105\u201312.","journal-title":"Obes Surg"},{"issue":"5","key":"1601_CR71","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/dom.15473","volume":"26","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, Sullivan E, Le P, Rothberg MB. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills. Diabetes Obes Metab. 2024;26(5):1687\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1601_CR72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11606-023-08501-z","volume":"39","author":"A Hung","year":"2024","unstructured":"Hung A, Wong ES, Dennis PA, et al. Real world use of anti-obesity medications and weight change in veterans. J Gen Intern Med. 2024;39(4):519\u201328.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1601_CR73","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.18553\/jmcp.2023.23083","volume":"29","author":"H Kan","year":"2023","unstructured":"Kan H, Bae JP, Dunn JP, et al. Real-world primary nonadherence to antiobesity medications. J Managed Care Spec Pharm. 2023;29(10):1099\u2013108.","journal-title":"J Managed Care Spec Pharm"},{"issue":"2","key":"1601_CR74","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/dom.13086","volume":"20","author":"B Gallwitz","year":"2018","unstructured":"Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once\u2010weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20(2):409\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"1601_CR75","doi-asserted-by":"crossref","unstructured":"Anichini R, Cosimi S, Di Carlo A et al. Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes. 2013;6:123\u20139.","DOI":"10.2147\/DMSO.S42729"},{"issue":"5","key":"1601_CR76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.EJ16-0552","volume":"64","author":"Y Onishi","year":"2017","unstructured":"Onishi Y, Oura T, Matsui A, Matsuura J, Iwamoto N. Analysis of efficacy and safety of dulaglutide 0.75\u00a0mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr J. 2017;64(5):553\u201360.","journal-title":"Endocr J"},{"issue":"4","key":"1601_CR77","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","volume":"30","author":"H Quan","year":"2016","unstructured":"Quan H, Zhang H, Wei W, Fang T. Gender-related different effects of a combined therapy of exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus. J Diabetes Complications. 2016;30(4):686\u201392.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"1601_CR78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"1601_CR79","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","volume":"55","author":"RV Overgaard","year":"2016","unstructured":"Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0\u00a0mg for weight management: a population Pharmacokinetic analysis. Clin Pharmacokinet. 2016;55:1413\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1601_CR80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","volume":"18","author":"J Wilding","year":"2016","unstructured":"Wilding J, Overgaard R, Jacobsen L, Jensen C, Le Roux C. Exposure\u2013response analyses of liraglutide 3.0\u00a0mg for weight management. Diabetes Obes Metab. 2016;18(5):491\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1601_CR81","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA, et al. Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials. J Am Coll Cardiol. 2024;84(9):773\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"1601_CR82","volume-title":"Body weight reduction associated with Tirzepatide by sex: A subgroup analysis of the SURMOUNT clinical trials. Presented at","author":"AM Chao","year":"2024","unstructured":"Chao AM, Taylor R, Mojdami D, Forrester T, Chigutsa FB, Malik R. Body weight reduction associated with Tirzepatide by sex: A subgroup analysis of the SURMOUNT clinical trials. Presented at. Boston, MA: Endocrine Society. 2024."},{"issue":"6","key":"1601_CR83","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple\u2013hormone-receptor agonist Retatrutide for obesity\u2014a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"key":"1601_CR84","doi-asserted-by":"crossref","unstructured":"Verma S, Colhoun HM, Dicker D et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) outcomes by sex. J Am Coll Cardiol. 2024;84(17):1678\u201382.","DOI":"10.1016\/j.jacc.2024.08.022"},{"issue":"1","key":"1601_CR85","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1038\/s41598-020-74000-4","volume":"10","author":"K-I Joung","year":"2020","unstructured":"Joung K-I, Jung G-W, Park H-H, Lee H, Park S-H, Shin J-Y. Gender differences in adverse event reports associated with antidiabetic drugs. Sci Rep. 2020;10(1):17545.","journal-title":"Sci Rep"},{"key":"1601_CR86","doi-asserted-by":"crossref","unstructured":"Eisenberg D, Shikora SA, Aarts E, et al. 2022 American society of metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO) indications for metabolic and bariatric surgery. Springer; 2023.","DOI":"10.1007\/s11695-022-06332-1"},{"issue":"10","key":"1601_CR87","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1007\/s11695-023-06722-z","volume":"33","author":"T Bharani","year":"2023","unstructured":"Bharani T, Sheu EG, Robinson MK. Procedure matters in gender-associated outcomes following metabolic-bariatric surgery: five year North American matched cohort analysis. Obes Surg. 2023;33(10):3090\u20136.","journal-title":"Obes Surg"},{"issue":"1","key":"1601_CR88","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1038\/s41598-021-92254-4","volume":"11","author":"P Mousapour","year":"2021","unstructured":"Mousapour P, Tasdighi E, Khalaj A, et al. Sex disparity in laparoscopic bariatric surgery outcomes: a matched-pair cohort analysis. Sci Rep. 2021;11(1):12809.","journal-title":"Sci Rep"},{"key":"1601_CR89","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1007\/s00464-019-07106-0","volume":"34","author":"N Dugan","year":"2020","unstructured":"Dugan N, Thompson KJ, Barbat S, et al. Male gender is an independent risk factor for patients undergoing laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass: an MBSAQIP\u00ae database analysis. Surg Endosc. 2020;34:3574\u201383.","journal-title":"Surg Endosc"},{"key":"1601_CR90","doi-asserted-by":"crossref","unstructured":"Beiglb\u00f6ck H, M\u00f6rth E, Reichardt B et al. Sex-specific differences in mortality of patients with a history of bariatric surgery: a nation-wide population-based study. Obes Surg. 2022;32(1):8\u201317.","DOI":"10.1007\/s11695-021-05763-6"},{"issue":"7","key":"1601_CR91","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.soard.2022.03.022","volume":"18","author":"R Risi","year":"2022","unstructured":"Risi R, Rossini G, Tozzi R, et al. Sex difference in the safety and efficacy of bariatric procedures: a systematic review and meta-analysis. Surg Obes Relat Dis. 2022;18(7):983\u201396. This systematic review and meta-analysis investigated the impact of sex on the efficacy and safety outcomes of bariatric procedures, finding that men tend to have greater BMI loss while women are more likely to be classified as weight responders and experience higher excess weight loss.","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"1601_CR92","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamasurg.2018.5084","volume":"154","author":"S Hjorth","year":"2019","unstructured":"Hjorth S, N\u00e4slund I, Andersson-Assarsson JC, et al. Reoperations after bariatric surgery in 26 years of follow-up of the Swedish obese subjects study. JAMA Surg. 2019;154(4):319\u201326.","journal-title":"JAMA Surg"},{"key":"1601_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-017-0784-8","volume":"19","author":"JS Tronieri","year":"2017","unstructured":"Tronieri JS, Wurst CM, Pearl RL, Allison KC. Sex differences in obesity and mental health. Curr Psychiatry Rep. 2017;19:1\u201311.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"1601_CR94","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.psychres.2009.04.015","volume":"178","author":"L De Wit","year":"2010","unstructured":"De Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230\u20135.","journal-title":"Psychiatry Res"},{"key":"1601_CR95","doi-asserted-by":"crossref","first-page":"769309","DOI":"10.3389\/fendo.2021.769309","volume":"12","author":"M Afzal","year":"2021","unstructured":"Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol. 2021;12:769309.","journal-title":"Front Endocrinol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01601-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-025-01601-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01601-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:31:17Z","timestamp":1744785077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-025-01601-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s11920-025-01601-z","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"4 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMC has served on advisory boards for Eli Lilly and Company and Boehringer Ingelheim and received grant support, on behalf of the University of Pennsylvania, from Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"AMC has served on advisory boards for Eli Lilly and Company and Boehringer Ingelheim and received grant support, on behalf of the University of Pennsylvania, from Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}